<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Hammouda MB</dc:creator>
  <dc:creator>Riahi-Chebbi I</dc:creator>
  <dc:creator>Souid S</dc:creator>
  <dc:creator>Othman H</dc:creator>
  <dc:creator>Aloui Z</dc:creator>
  <dc:creator>Srairi-Abid N</dc:creator>
  <dc:creator>Karoui H</dc:creator>
  <dc:creator>Gasmi A</dc:creator>
  <dc:creator>Magnenat EM</dc:creator>
  <dc:creator>Wells TNC</dc:creator>
  <dc:creator>Clemetson KJ</dc:creator>
  <dc:creator>Rodríguez-López JN</dc:creator>
  <dc:creator>Essafi-Benkhadir K</dc:creator>
  <dc:date>2018</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">BACKGROUND
The resistance of melanoma cells to cisplatin restricts its clinical use. Therefore, the search for novel tumor inhibitors and effective combination treatments that sensitize tumor cells to this drug are still needed. We purified macrovipecetin, a novel heterodimeric C-type lectin, from Macrovipera lebetina snake venom and investigated its anti-tumoral effect on its own or combined with cisplatin, in human melanoma cells.


METHODS
Biochemical characterization, in vitro cells assays such as viability, apoptosis, adhesion, migration, invasion, Western blotting and in silico analysis were used in this study.


RESULTS
Macrovipecetin decreased melanoma cell viability 100 times more than cisplatin. Interestingly, when combined with the drug, macrovipecetin enhanced the sensitivity of SK-MEL-28 cells by augmenting their apoptosis through increased expression of the apoptosis inducing factor (AIF) and activation of ERK1/2, p38, AKT and NF-κB. Moreover, macrovipecetin alone or combined with cisplatin induced the expression of TRADD, p53, Bax, Bim and Bad and down-regulated the Bcl-2 expression and ROS levels in SK-MEL-28 cells. Interestingly, these treatments impaired SK-MEL-28 cell adhesion, migration and invasion through modulating the function and expression of αvβ3 integrin along with regulating E-cadherin, vimentin, β-catenin, c-Src and RhoA expression. In silico study suggested that only the α chain of macrovipecetin interacts with a region overlapping the RGD motif binding site on this integrin.


CONCLUSIONS
We validated the antitumor effect of macrovipecetin when combined, or not, with cisplatin on SK-MEL-28 cells.


GENERAL SIGNIFICANCE
The presented work proposes the potential use of macrovipecetin and cisplatin in combination as an effective anti-melanoma treatment.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/278667</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.bbagen.2017.11.019</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/29196192</dc:relation>
  <dc:source>Biochimica et biophysica acta. General subjects. - 2018</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Anti-tumoral effect</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Cisplatin efficacy</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Macrovipecetin</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Mechanistic characterization</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Melanoma</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Snaclec</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Amino Acid Sequence</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Animals</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Antineoplastic Agents</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Antineoplastic Agents, Alkylating</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Apoptosis</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Apoptosis Regulatory Proteins</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Cell Adhesion</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Cell Adhesion Molecules</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Cell Line, Tumor</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Cell Movement</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">Cisplatin</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Drug Resistance, Neoplasm</dc:subject>
  <dc:subject xmlns:ns19="xml" ns19:lang="en">Drug Screening Assays, Antitumor</dc:subject>
  <dc:subject xmlns:ns20="xml" ns20:lang="en">Drug Synergism</dc:subject>
  <dc:subject xmlns:ns21="xml" ns21:lang="en">Gene Expression Regulation, Neoplastic</dc:subject>
  <dc:subject xmlns:ns22="xml" ns22:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns23="xml" ns23:lang="en">Integrin alphaVbeta3</dc:subject>
  <dc:subject xmlns:ns24="xml" ns24:lang="en">Lectins, C-Type</dc:subject>
  <dc:subject xmlns:ns25="xml" ns25:lang="en">Melanoma</dc:subject>
  <dc:subject xmlns:ns26="xml" ns26:lang="en">Models, Molecular</dc:subject>
  <dc:subject xmlns:ns27="xml" ns27:lang="en">Molecular Docking Simulation</dc:subject>
  <dc:subject xmlns:ns28="xml" ns28:lang="en">Neoplasm Invasiveness</dc:subject>
  <dc:subject xmlns:ns29="xml" ns29:lang="en">Neoplasm Proteins</dc:subject>
  <dc:subject xmlns:ns30="xml" ns30:lang="en">Protein Conformation</dc:subject>
  <dc:subject xmlns:ns31="xml" ns31:lang="en">Protein Interaction Domains and Motifs</dc:subject>
  <dc:subject xmlns:ns32="xml" ns32:lang="en">Protein Interaction Mapping</dc:subject>
  <dc:subject xmlns:ns33="xml" ns33:lang="en">Sequence Alignment</dc:subject>
  <dc:subject xmlns:ns34="xml" ns34:lang="en">Sequence Homology, Amino Acid</dc:subject>
  <dc:subject xmlns:ns35="xml" ns35:lang="en">Viper Venoms</dc:subject>
  <dc:subject xmlns:ns36="xml" ns36:lang="en">Viperidae</dc:subject>
  <dc:title xmlns:ns37="xml" ns37:lang="en">Macrovipecetin, a C-type lectin from Macrovipera lebetina venom, inhibits proliferation migration and invasion of SK-MEL-28 human melanoma cells and enhances their sensitivity to cisplatin.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
